Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other Non-Current Liabilities (2023 - 2025)

Kura Oncology (KURA) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 76.32% to $3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 million, a 76.32% increase, with the full-year FY2025 number at $3.2 million, up 76.32% from a year prior.
  • Other Non-Current Liabilities was $3.2 million for Q4 2025 at Kura Oncology, up from $3.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.2 million in Q4 2025 to a low of $351000.0 in Q1 2023.
  • A 3-year average of $1.5 million and a median of $1.3 million in 2024 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 170.94% in 2024, then skyrocketed 76.32% in 2025.
  • Kura Oncology's Other Non-Current Liabilities stood at $705000.0 in 2023, then skyrocketed by 154.61% to $1.8 million in 2024, then surged by 76.32% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Other Non-Current Liabilities are $3.2 million (Q4 2025), $3.0 million (Q3 2025), and $2.6 million (Q2 2025).